CarnaBioC1763102:Oral AS-1763 in Previous Treated Lymphoma or Non-Hodgkin Lymphoma

Purpose of this Study

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.

Who Can Participate?

Eligibility

Adults and children younger than 65 who:

Are diagnosed with lymphoma or non-Hodgkin lymphoma
Have at least 1 radiographically measurable lesion
Have been treated with at least 2 previous lines of therapy that were not effective

For more information, contact the study team at tenesia.carey@duke.edu.

Age Range

0-64

Sex/Genders

Male (cisgender)

Female (cisgender)

Non-binary or gender fluid

Transgender male

Transgender female

Looking for Healthy Participants

What is Involved?

Description

If you choose to join this study, you will get a random assignment (by chance) to take a certain dose of the study drug. The dose levels you might get are:

300 mg; OR
400 mg; OR
500 mg

Depending on your treatment history and when you join the study, you might receive any of these 3 dose levels or you might receive either the 400 mg or 500 mg dose. The study team will let you know what dose levels are possibilities for you before you choose to join the study. This study will last for approximately 22 months and involve about 29 visits to our clinic.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

Study Details

Full Title

A Phase 1b Study of Oral AS-1763 in Patients with Previously
Treated Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma or Non-Hodgkin Lymphoma

Principal Investigator

Danielle

Brander

Protocol Number

PRO00116810

NCT ID

NCT05602363

Phase

Enrollment Status

Pending Open to Enrollment

ClinicalTrials.gov